Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS‑13 in patients with lung cancer

Liu,Xia; Chen,Xiaogang; Yang,Jiezuan; Guo,Renyong

doi:10.3892/ol.2017.6619

Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS‑13 in patients with lung cancer

Authors:
- Xia Liu
- Xiaogang Chen
- Jiezuan Yang
- Renyong Guo
View Affiliations

Affiliations: Department of Intensive Care Unit, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Laboratory Medicine, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: July 20, 2017 https://doi.org/10.3892/ol.2017.6619
Pages: 3787-3794

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Coagulative and fibrinolytic disorders appear to be associated with the development of lung cancer. The aim of the present study was to determine plasma levels of von Willebrand factor (VWF) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 (ADAMTS‑13), and factor VIII (FVIII) activity, in association with O and non‑O blood groups in patients with lung cancer. Plasma levels of VWF and ADAMTS‑13, and FVIII activity were measured in 115 patients with lung cancer and 98 healthy subjects. Phenotyping of the ABO blood groups was also performed for the two groups. Significantly increased VWF levels and FVIII activity, as well as significantly decreased ADAMTS‑13 levels, were observed in patients with distant metastasis as compared with those without distant metastasis and the healthy controls. Plasma VWF levels and FVIII activity were significantly increased in subjects with non‑O type blood compared with those with type O blood in the two groups. However, a significant decrease in ADAMTS‑13 levels was observed only in the control group among those with non‑O type blood, compared with those with type O blood. The results of the present study indicate that increased VWF and decreased ADAMTS‑13 levels facilitate the invasiveness and metastasis of lung cancer. Non‑O blood groups constitute a risk factor for increased VWF and FVIII in plasma. Continued monitoring of VWF and ADAMTS‑13 levels, and of FVIII activity in patients with lung cancer with distinct blood groups may help to minimize the incidence of thrombotic events and improve assessment of disease progression.

View Figures

View References

1	Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H and Suzuki S: Evaluating prethrombotic state in lung cancer using molecular markers. Chest. 103:196–200. 1993. View Article : Google Scholar : PubMed/NCBI
2	Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y and Mishima M: Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. Med Oncol. 28:351–356. 2011. View Article : Google Scholar : PubMed/NCBI
3	Tas F, Kilic L, Serilmez M, Keskin S, Sen F and Duranyildiz D: Clinical and prognostic significance of coagulation assays in lung cancer. Respir Med. 107:451–457. 2013. View Article : Google Scholar : PubMed/NCBI
4	Terraube V, O'Donnell JS and Jenkins PV: Factor VIII and von Willebrand factor interaction: Biological, clinical and therapeutic importance. Haemophilia. 16:3–13. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sporn LA, Marder VJ and Wagner DD: Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 46:185–190. 1986. View Article : Google Scholar : PubMed/NCBI
6	Sadler JE: Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 67:395–424. 1998. View Article : Google Scholar : PubMed/NCBI
7	Fujikawa K, Suzuki H, McMullen B and Chung D: Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 98:1662–1666. 2001. View Article : Google Scholar : PubMed/NCBI
8	Moake JL: Thrombotic microangiopathies. N Engl J Med. 347:589–600. 2002. View Article : Google Scholar : PubMed/NCBI
9	Franchini M, Favaloro EJ, Targher G and Lippi G: ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci. 49:137–149. 2012. View Article : Google Scholar : PubMed/NCBI
10	Jenkins PV and O'Donnell JS: ABO blood group determines plasma von Willebrand factor levels: A biologic function after all? Transfusion. 46:1836–1844. 2006. View Article : Google Scholar : PubMed/NCBI
11	Sousa NC, Anicchino-Bizzacchi JM, Locatelli MF, Castro V and Barjas-Castro ML: The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica. 92:236–239. 2007. View Article : Google Scholar : PubMed/NCBI
12	Terraube V, Marx I and Denis CV: Role of von Willebrand factor in tumor metastasis. Thromb Res. 120:(Suppl 2). S64–S70. 2007. View Article : Google Scholar : PubMed/NCBI
13	Martini F, Ferroni P, Guadagni F, Basili S, Spila A, D'Alessandro R, Mineo D, Laudisi A, Portarena I, Mariotti S, et al: Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients. Anticancer Res. 25:403–407. 2005.PubMed/NCBI
14	Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
15	Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest. 136:260–271. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bais R and Philcox M: Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 8. IFCC method for lactate dehydrogenase (l-lactate: NAD+oxidoreductase, EC 1.1.1.27). International Federation of Clinical Chemistry (IFCC). Eur J Clin Chem Clin Biochem. 32:639–655. 1994.PubMed/NCBI
17	Okuno T and Selenko V: Plasma fibrinogen determination by automated thrombin time. Am J Med Technol. 38:196–201. 1972.PubMed/NCBI
18	Elf JL, Strandberg K and Svensson PJ: Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis. Thromb Res. 124:701–705. 2009. View Article : Google Scholar : PubMed/NCBI
19	Barrowcliffe TW, Raut S, Sands D and Hubbard AR: Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations. Semin Thromb Hemost. 28:247–256. 2002. View Article : Google Scholar : PubMed/NCBI
20	Goad KE and Gralnick HR: Coagulation disorders in cancer. Hematol Oncol Clin North Am. 10:457–484. 1996. View Article : Google Scholar : PubMed/NCBI
21	Guadagni F, Ferroni P, Basili S, Facciolo F, Carlini S, Crecco M, Martini F, Spila A, D'Alessandro R, Aloe S, et al: Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients. Lung Cancer. 44:303–310. 2004. View Article : Google Scholar : PubMed/NCBI
22	Oleksowicz L, Bhagwati N and DeLeon-Fernandez M: Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res. 59:2244–2250. 1999.PubMed/NCBI
23	Unsal E, Atalay F, Atikcan S and Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 98:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
24	Sugimoto Y, Watanabe M, Oh-Hara T, Sato S, Isoe T and Tsuruo T: Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Res. 51:921–925. 1991.PubMed/NCBI
25	Oleksowicz L, Bhagwati N, Fernandez MD, Seno R and Etkind P: Prognostic significance of platelet immunorelated GPIb expression in breast cancer. Cancer J Sci Am. 4:247–253. 1998.PubMed/NCBI
26	León-Atance P, Moreno-Mata N, González-Aragoneses F, Cañizares-Carretero MÁ, Poblet-Martínez E, Genovés-Crespo M, García-Jiménez MD, Honguero-Martínez AF, Rombolá CA, Simón-Adiego CM, et al: Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer. Arch Bronconeumol. 48:49–54. 2012.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
27	Joh HK, Cho E and Choueiri TK: ABO blood group and risk of renal cell cancer. Cancer Epidemiol. 36:528–532. 2012. View Article : Google Scholar : PubMed/NCBI
28	Oguz A, Unal D, Tasdemir A, Karahan S, Aykas F, Mutlu H, Cihan YB and Kanbay M: Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev. 14:453–456. 2013. View Article : Google Scholar : PubMed/NCBI
29	Urun Y, Utkan G, Cangir AK, Oksuzoglu OB, Ozdemir N, Oztuna DG, Kocaman G, Coşkun HŞ, Kaplan MA, Yuksel C, et al: Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey. Asian Pac J Cancer Prev. 14:2801–2803. 2013. View Article : Google Scholar : PubMed/NCBI
30	Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, et al: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 41:986–990. 2009. View Article : Google Scholar : PubMed/NCBI
31	Suadicani P, Hein HO and Gyntelberg F: ABO phenotypes and inflammation-related predictors of lung cancer mortality: The Copenhagen Male Study-a 16-year follow-up. Eur Respir J. 30:13–20. 2007. View Article : Google Scholar : PubMed/NCBI
32	Klarmann D, Eggert C, Geisen C, Becker S, Seifried E, Klingebiel T and Kreuz W: Association of ABO(H) and I blood group system development with von Willebrand factor and factor VIII plasma levels in children and adolescents. Transfusion. 50:1571–1580. 2010. View Article : Google Scholar : PubMed/NCBI
33	Bowen DJ: An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 1:33–40. 2003. View Article : Google Scholar : PubMed/NCBI
34	Wagner DD, Mayadas T and Marder VJ: Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 102:1320–1324. 1986. View Article : Google Scholar : PubMed/NCBI
35	Choi Q, Kim JE, Kim SY, Han KS and Kim HK: Influence of ABO type on global coagulation assay results: Effect of coagulation factor VIII. Clin Chem Lab Med. 53:1425–1432. 2015. View Article : Google Scholar : PubMed/NCBI
36	Mannucci PM, Capoferri C and Canciani MT: Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 126:213–218. 2004. View Article : Google Scholar : PubMed/NCBI